There is No Better Way to Cure a Broken Heart® Board of Directors
Thom Rasche
Partner, Earlybird
Thom Rasche joined Earlybird as a Venture Partner in 2003 and was promoted to Partner in 2006. He is a seasoned executive in the medical device and diagnostic sectors with over 20 years of operational experience.
Since he joined Earlybird, Thom has been responsible for the medical device portfolio and for making new investments in this area. He has successfully led various financing rounds in both European and US based medical device companies before the investment in Miracor.
Thom is on the board of Zonare Medical Systems and has held various senior marketing and sales positions with Johnson & Johnson in Europe and the US. He holds a Degree as Diplom Kaufmann (MBA equivalent) from the University of Applied Sciences in Lüneburg, Germany, specializing in marketing and human resource management.
Joey Mason
M.D., Partner, Delta Partners
Dr Joey Mason joined Delta Partners in 2003, specialising in Life Science investments. He serves on the boards of Genable Technologies Ltd, Glysure Ltd, AccuNostics, Neuravi, Miracor Medical Systems GmbH, SpineGuard SA and as an observer on the board of QStream. Having trained as a doctor, Joey spent five years as an investment banker in the Health Care market with Morgan Stanley International and Technomark in London. From 1995 until 1999 he was Director of Corporate Development at Biotrin Holdings plc, an Irish biotechnology company backed by Delta Partners and other VCs. In 2000 he co-founded and managed Eumom Ltd, a marketing services business which operates websites for pregnant women in Germany, Ireland, Switzerland and the UK. He is a director of Eumom Marketing Ltd. A medical graduate of Trinity College, Dublin, he is a Fellow of the RSA.
Hubertus Leonhardt
Partner, CFA, SHS
Hubertus is managing partner and finance director of the German life science investor SHS. SHS is a sector specialist in medical devices and diagnostics and is focused on investments in Germany, Austria and Switzerland. The investment in Miracor has been completed out of the third funds generation in 2011. SHS IV funds, also focusing on medtech and diagnostics is currently prepared for launch. SHS invested e.g. in 4a medicom, Phenox, Novosis Pharma, Vita 34 and Probiogen AG. Hubertus is in the venture capital industry since 1997, since then he has been responsible for several life science investments and exits. He has an degree in business management from Duale Hochschule, Mannheim, Baden Württemberg and post graduate qualifications as tax advisor and Chartered Financial Analyst. Previous to SHS he served as corporate finance project leader with the Frankfurt office of Arthur Andersen.
Werner Mohl
Founder & Chief Scientific Advisor
Prof. DDr., Medical University of Vienna, Austria
Prof. Mohl is the innovator behind the PICSO® concept and is a long term academic Professor of cardiac surgery at the Medical University of Vienna. Active in patient care, teaching and research of coronary hemodynamics, cardiac regeneration and cardioprotection he also serves as Chief Scientific Advisor on a consulting basis for Miracor. He holds a medical degree and a PhD from the University of Vienna, Austria.
Jon H. Hoem
CEO
Jon joined Miracor in May 2008 with 20 years experience in advanced medical device development and international sales&marketing in cardiology and cardiac surgery. For more details read under team.
